National Academies Press: OpenBook
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

New Vaccine Development Establishing Priorities

VOLUME II Diseases of Importance in Developing Countries

Part Two of a Two-Part Study by the

Committee on Issues and Priorities for New Vaccine Development

Division of Health Promotion and Disease Prevention and Division of International Health

INSTITUTE OF MEDICINE

NATIONAL ACADEMIES PRESS

Washington, D.C.
1986
www.nap.edu

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

NATIONAL ACADEMY PRESS
2101 CONSTITUTION AVE., NW WASHINGTON, DC 20418

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

This report has been reviewed by a group other than the authors according to procedures approved by a Report Review Committee consisting of members of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

The Institute of Medicine was chartered in 1970 by the National Academy of Sciences to enlist distinguished members of the appropriate professions in the examination of policy matters pertaining to the health of the public. In this, the Institute acts under both the Academy’s 1863 congressional charter responsibility to be an adviser to the federal government and its own initiative in identifying issues of medical care, research, and education.

The work on which this publication is based was initiated and funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract No. NO1-AI-22678. The U.S. Agency for International Development, through the Public Health Service’s Vaccine Development and Health Research Participating Agency Services Agreement No. 000001-04-S5, also provided valuable financial support.

Library of Congress Cataloging-in-Publication Data

(Revised for vol. 2)

New vaccine development.

Prepared for the National Institute of Allergy and Infectious Diseases.

Includes bibliographies and index.

Contents: v. 1. Diseases of importance in the United States—v. 2. Diseases of importance in developing countries.

1. Vaccines—Research—Government policy. 2. Communicable diseases—United States—Preventive inoculation. 3. Communicable diseases—Developing countries—Preventive inoculation. I. Institute of Medicine (U.S.). Committee on Issues and Priorities for New Vaccine Development. II. National Institute of Allergy and Infectious Diseases (U.S.)

RA638.N49 1985 614.4’7’0973 84–62037

ISBN 0-309-03494-9 (pbk.: v. 1)

ISBN 0-309-03679-8 (v. 2)

Printed in the United States of America

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Committee on Issues and Priorities for New Vaccine Development

SAMUEL L.KATZ (chair),

Department of Pediatrics, Duke University Medical Center

A.JOHN BEALE,

Wellcome Research Laboratories, United Kingdom

MARSHALL H.BECKER,

Department of Health Behavior and Health Education, University of Michigan, Ann Arbor

JAMES CHIN,

Department of Health Services, State of California Health and Welfare Agency, Berkeley

PURNELL W.CHOPPIN,

Howard Hughes Medical Institute, Bethesda, Md.

THEODORE C.EICKHOFF,

Department of Internal Medicine, Presbyterian/St Luke’s Medical Center, Denver

FRANCIS A.ENNIS,

Department of Medicine and Molecular Genetics, University of Massachusetts Medical Center, Worcester

HARVEY V.FINEBERG,

Institute for Health Research, Harvard School of Public Health

MAURICE R.HILLEMAN,

Merck Institute for Therapeutic Research, Merck Sharp & Dohme Research Laboratories

GERALD T.KEUSCH,

Division of Geographic Medicine, Tufts University

RICHARD F.KINGHAM,

Covington and Burling, Washington, D.C.

BERNARD ROIZMAN,

Department of Microbiology and Biophysics, University of Chicago

HENRY R.SHINEFIELD,

Department of Pediatrics, Kaiser Permanente Medical Group, San Francisco

JANE E.SISK,

Office of Technology Assessment, United States Congress

CLADD E.STEVENS,

Laboratory of Epidemiology, The New York Blood Center

LEROY WALTERS,

Kennedy Institute of Ethics, Georgetown University

MILTON C.WEINSTEIN,

Institute for Health Research, Harvard School of Public Health

See Appendix G for further information on committee members.

Institute of Medicine Staff

ROY WIDDUS, Study Director and Director,

Division of International Health

ENRIQUETA C.BOND, Director,

Division of Health Promotion and Disease Prevention

GUTHRIE BIRKHEAD, Consultant

CYNTHIA HOWE, Research Assistant

ELAINE MCGARRAUGH, Staff Associate

EVE K.NICHOLS, Editor

JUDE C.PAYNE, Research Assistant

GAIL E.SPEARS, Administrative Secretary

NORA STEINER, Research Assistant

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Consultants

FAKHRY ASSAAD,

Division of Communicable Diseases, World Health Organization, Geneva

NATTH BHAMARAPRAVATI,

Mahidol University, Thailand

CHARLES C.J.CARPENTER,

Department of Medicine, Case Western Reserve University

FEDERICO CHAVEZ-PEON,

Industria Paraestatal Farmaceutica, FISOMEX, Mexico

SCOTT HALSTEAD,

Health Sciences Division, The Rockefeller Foundation

KARL M.JOHNSON,

Hoffman-LaRoche, Incorporated

ADETOKUNBO O.LUCAS,

Special Programme for Research and Training in Tropical Diseases, World Health Organization

ARNOLD S.MONTO,

School of Public Health, University of Michigan

FRANKLIN A.NEVA,

National Institute of Allergy and Infectious Diseases, National Institutes of Health

S.RAMACHANDRAN,

Department of Science and Technology, Government of India

JOHN B.ROBBINS,

National Institute of Child Health and Human Development, National Institutes of Health

JONAS SALK,

The Salk Institute for Biological Studies

DONALD S.SHEPARD,

Institute for Health Research, Harvard School of Public Health

DAVID H.SMITH,

Department of Pediatrics, University of Rochester

PHILIPPE STOECKEL,

Association pour la Promotion de la Medicine Preventive, Paris

JULIA WALSH,

Harvard Medical School

KENNETH WARREN,

Health Sciences Division, The Rockefeller Foundation

THOMAS H.WELLER,

Department of Tropical Public Health, Harvard School of Public Health

National Institute of Allergy and Infectious Diseases Steering Committee

ROBERT M.CHANOCK, Chief,

Laboratory of Infectious Diseases

WILLIAM JORDAN, Director,

Microbiology and Infectious Diseases Program

JOHN E.NUTTER, Chief,

Office of Program Planning and Evaluation

BERNARD TALBOT, Deputy Director,

National Institute of Allergy and Infectious Diseases

C.DAVID WISE, Chief,

Evaluation Section, Office of Program Planning and Evaluation

U.S. Agency for International Development Advisors

GEORGE T.CURLIN, Assistant Director for Health Research,

Office of International Health, Public Health Service

KENNETH J.BART, Director,

Office of Health, U.S. Agency for International Development

Liaison Committee

BENNETT ELISBERG, Director,

Division of Product Quality Control, Food and Drug Administration

ALAN HINMAN, Director,

Division of Immunization, Center for Prevention Services, Centers for Disease Control

JEFFREY KOPLAN, Assistant Director for Public Health Practice,

Centers for Disease Control

PHILIP K.RUSSELL, Commander General,

Fitzsimmons Army Medical Center

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Acknowledgements

This report could not have been prepared without the assistance of many individuals who willingly gave their valuable time to provide information and advice, and to prepare or comment on draft sections of the final document. A list of those to whom the committee is particularly indebted appears as Appendix H. It is possible that some individuals may have been omitted from this list by oversight. If this has happened, the committee offers its sincere apologies.

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Preface

This volume is the second report from the Institute of Medicine’s Committee on Issues and Priorities for New Vaccine Development. The first report dealt with vaccines for diseases of importance in the United States. The purpose of this volume is to help in setting priorities for the accelerated development of vaccines against diseases prevalent in developing countries. The background of the study and the committee’s approach were outlined in the preface to Volume I, which is reprinted in Appendix J. The project was initiated by the National Institute of Allergy and Infectious Diseases, which provided major funding for the overall effort. For the second phase of the project on diseases of importance in developing countries, valuable financial support was also provided by the U.S. Agency for International Development.

In the second phase of the study, the committee made particular efforts to draw on the expertise and opinions of individuals who have worked extensively in public health fields in developing countries. Consultants from several parts of the world attended a meeting of the committee in August 1984, and many others contributed views by mail or telephone.

Any group assessing vaccine development—whether for disease afflicting the United States population or mankind in general—would be sorely remiss if it omitted consideration of acquired immune deficiency syndrome (AIDS). As the committee was completing its first analysis, reports identifying the probable etiologic agent of AIDS were emerging, scarcely three to four years after the recognition of the syndrome. At that time, the committee believed that comparison of AIDS vaccine prospects with those of other advanced candidates for accelerated vaccine development would have been premature.

In the ensuing year remarkable progress has been made, largely because of the powerful molecular and cellular biotechnologies that have emerged from basic biomedical research. Yet, significant questions remain before the prospects for vaccine development can be assessed clearly or its priority relative to other diseases evaluated. Uncertainty and apprehension as to the increasing magnitude of the problem (both domestic and global) is but one reason why this disease may merit separate consideration.

The state of knowledge in this area is now approaching that where consideration can be given to the question of accelerated AIDS vaccine development. However, the Committee on Issues and Priorities for New Vaccine Development elected to forgo the option of including AIDS in this volume, because of the fact that at the time this volume was nearing completion the Institute of Medicine and the National Academy of Sciences, in consortium, had embarked on an intensive assessment of research needs and opportunities and treatment and health care issues related to AIDS. That exercise, scheduled for completion in the fall of 1986, includes consideration of vaccine prospects.

Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

The committee gratefully acknowledges the assistance provided by its consultants (listed above) and other advisers listed in Appendix H. It also wishes to take particular note of the continued excellent support of the Institute of Medicine staff headed by Roy Widdus. The assistance and advice of the National Institute of Allergy and Infectious Diseases project officer, C.David Wise, is also gratefully acknowledged, as is that provided by George T.Curlin, of the Public Health Service, on behalf of the Agency for International Development.

Samuel L.Katz

Chairman

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Abstract

This report describes a method designed to aid government decision makers in establishing priorities for accelerated development of vaccines against diseases of importance in developing countries. The method is based on a quantitative model in which vaccine candidates are ranked according to their potential health benefits (reduction of morbidity and mortality). The model also provides the capacity to utilize “affordability” (willingness to pay for benefit) as a supplementary criterion.

The approach uses the same (incomplete) information that could theoretically be used in other methods of decision making. Because the information is incomplete and because the method entails, in some instances, predicting the future, gaps must be filled by estimates or judgments by experts. Commentary is included in Chapter 1 to explain the advantages of the system and to prevent misinterpretation of the power and precision of the method.

The committee believes that final selection of priorities should be made after decision makers have evaluated certain nonquantifiable considerations discussed in the report, but not incorporated into the model. These include the goals of the agency and its schedule for achieving them, considerations of equity or intent in the distribution of benefits, the opportunity and need for the agency to exert influence on development, the balance of the desired portfolio of vaccine development projects, and certain other nonquantifiable factors relating to the diseases and alternative control approaches.

The method was applied to 29 vaccine candidates for 19 diseases of importance in the developing world where new or improved vaccines were judged technically feasible within the next decade. (A prior assessment considered vaccines for diseases of importance in the United States). Costs and benefits are viewed from a perspective for the developing world as a whole. The committee did not address the issues of balance between basic scientific research and vaccine development, and it expressly refrained from placing a monetary value on health benefits.

An important early step in the evaluation of a potential vaccine is the selection of an appropriate target population. The committee assumed that vaccine utilization within target populations would be uniform because delivery was likely to be through the World Health Organization Expanded Program on Immunization. However, techniques are described for incorporating differential utilization, if desired. A new technique was designed to compare quantitatively the health impacts of diseases and vaccines using units of “mortality equivalents.”

Elements incorporated into the calculation of a vaccine’s expected health benefit include data (and estimates) on the disease burden resulting from each pathogen, value judgments on the undesirability of conditions arising from the disease, the proportion of the disease falling in the target population, various predictions on the vaccine’s development (e.g., probability of success), and its characteristics (e.g., efficacy and the time before benefits would be achieved). The way in which value judgments on the undesirability of conditions resulting from disease (e.g., levels of acute and chronic morbidity, infertility, or death) are incorporated into the system allows quantitative expression of any perspective and an examination of its effects on the ranking. The perspective used to illustrate application of the method was

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

the median of responses from a number of health professionals in a range of developing countries. (The committee, however, does not endorse this or any other specific perspective for policy formulation in this area.)

A comprehensive assessment of the net expected costs (possibly savings) associated with each vaccine candidate would include the cost of vaccine development, the likely cost of the vaccination program, the expected cost savings from treatment averted, and the cost of adverse reactions. Procedures to perform these calculations (conducted for the domestic U.S. analysis) are described in the report. For this analysis the committee judged it was not practical or realistic to attempt to estimate, for the entire developing world, the typical treatments for various disease conditions and their average costs. Thus, the cost components in this analysis relate to expenditures necessary to achieve the vaccine benefits, that is, the cost of development and the cost of vaccine for the immunization programs. (Delivery and administration costs, like utilization, are assumed to be uniform.) No “indirect” economic measures of health outcome were used.

Implementing the method requires substantial amounts of information about diseases and vaccine characteristics. Data having the desired degree of reliability are not always available, however. When data are unavailable, expert judgments are required to quantify factors that are incorporated into the calculations. Scientific opinions differ on some of these judgments (e.g., the probability of success), and uncertainty surrounds much of the data (e.g., disease incidence and efficacy). The method requires the user to identify and be explicit about such factors, which the committee believes is preferable to leaving them unspecified, amorphous, or unquantified. The attempt to be explicit about certain estimates should not, however, be interpreted as an indication that a high degree of precision, unanimity, or certainty in comparisons is currently possible.

The final format is flexible, can be updated as necessary to assess new vaccine candidates or to reassess current contenders, and allows users to vary estimates or predictions across a range of plausible values to determine their effects on the final result. The results from several sensitivity analyses indicate that the rank order of candidates remains fairly stable for the issues tested, which include different discount rates, probabilities of success, and various levels of financial resource constraint. Additional analyses are suggested to provide further information on the key elements that affect decisions and to indicate where new information is most needed.

The table on page xi shows the categories into which the assessed vaccine candidates fall under a fairly wide range of assumptions and resource availabilities. Because certain candidates may enter different categories if other plausible assumptions are adopted, the assignments in the table should not be regarded as definitive.

The committee recommends use of the method to government decision makers. The capacity to make rational choices on vaccine development priorities and vaccine formulation would be enhanced by better information on disease incidence and the pathogen serotypes prevalent in particular regions. Therefore, NIAID and other national and international agencies should consider means of improving the epidemiologic information on infectious diseases.

After the committee achieved consensus on vaccine development predictions (late summer 1985), preliminary unpublished results from certain ongoing studies came to their attention. These results, if confirmed, may slightly alter the predictions on some vaccine candidates, particularly on candidates targeted against the same pathogen relative to each other, e.g., as for cholera and rotavirus. The committee did not conduct calculations based on the preliminary information but believes it would not significantly alter the overall conclusions described above; it recommends early reappraisal of candidate ranking as data from ongoing studies are publicly reported.

An improved vaccine for hepatitis B virus (a polypeptide produced by recombinant DNA technology), predicted by the committee to be licensed in 1 year or less, was in fact licensed on July 24, 1986.

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Summary of Findings: Rankings of Various Vaccine Candidates Based on Their Potential Health Benefits Under a Variety of Assumptions and Resource Constraints

High

Intermediate

Low

S.pneumoniae

Plasmodium spp. (malaria; both monovalent and circumsporozoite protein-based approaches)

Rotavirus (all three candidates)

S.typhi (Ty21a)

Shigella spp.

Hepatitis B virus

H.influenzae type b

E.coli (either candidate)

Streptococcus group A

S.typhi (an aromatic amino acid-requiring strain)

M.leprae

V.cholerae (either candidate)

Respiratory syncytial virus (either candidate)

Parainfluenza

Rabies (vero cell derived or glycoprotein)

Hepatitis A (either candidate)

N.meningitidis

Yellow fever virus

Dengue

Rabies (live vector virus)

Japanese encephalitis virus

NOTE: Because certain vaccine candidates may enter different categories if other plausible assumptions are adopted, these assignments should not be regarded as definitive.

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

This page intentionally left blank.

Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Contents

1.   Summary

 

1

2.   Priority Setting for Health-Related Investments: A Review of Methods

 

19

3.   Overview of the Analytic Approach

 

30

4.   Comparison of Disease Burdens

 

44

5.   Predictions on Vaccine Development

 

63

6.   Assessing the Likely Utilization of New Vaccines

 

76

7.   Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines

 

82

8.   Additional Issues in the Selection of Priorities for Accelerated Vaccine Development

 

106

9.   Findings, Conclusions, and Recommendations

 

121

APPENDIXES

 

 

A   Selection of Vaccine Candidates for Accelerated Development

 

143

B   The Burden of Disease Resulting from Acute Respiratory Illness

 

149

C   The Burden of Disease Resulting from Diarrhea

 

159

D-1   The Prospects for Immunizing Against Dengue Virus

 

170

D-2   The Prospects for Immunizing Against Escherichia coli

 

178

D-3   The Prospects for Immunizing Against Hemophilus influenzae Type b

 

186

D-4   The Prospects for Immunizing Against Hepatitis A Virus

 

197

D-5   The Prospects for Immunizing Against Hepatitis B Virus

 

208

D-6   The Prospects for Immunizing Against Japanese Encephalitis Virus

 

223

D-7   The Prospects for Immunizing Against Mycobacterium leprae

 

241

D-8   The Prospects for Immunizing Against Neisseria meningitidis

 

251

D-9   The Prospects for Immunizing Against Parainfluenza Viruses

 

267

D-10   The Prospects for Immunizing Against Plasmodium spp.

 

275

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

New Vaccine Development

Establishing Priorities

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R1
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R2
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R3
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R4
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R5
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R6
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R7
Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R8
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R9
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R10
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R11
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R12
Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R13
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R14
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R15
Suggested Citation:"Front Matter." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page R16
Next: 1. Summary »
New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries Get This Book
×
Buy Paperback | $65.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Common diseases cost the developing world an enormous amount in terms of human life, health, and productivity, as well as lost economic potential. New and effective vaccines could not only improve the quality of life for millions of residents in developing countries, they could also contribute substantially to further economic development. Using data from the World Health Organization and other international agencies, this book analyzes disease burdens, pathogen descriptions, geographic distribution of diseases, probable vaccine target populations, alternative control measures and treatments, and future prospects for vaccine development. New Vaccine Development provides valuable insight into immunological and international health policy priorities.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!